- CDC News
- Adult Immunization
- Hepatology
- Rare Disorders
- Pediatric Immunization
- Weight Management
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Kidney Disease
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Orthopedics
- Obesity Medicine
- Rheumatology
- Technology
- Oncology
- Nephrology
- Neurology
- Pulmonology
6 Biologics for Severe Asthma, 3 Essential Facts on Each
Severe asthma affects up to 10% of adults and 2.5% of children with asthma and is characterized by cytokine-driven type 2 (T2) inflammation. For many individuals with severe disease, T2 inflammation is supressed by use of inhaled and/or oral glucocorticoids. For a subgroup, however, airway eosinophilia persists despite the use of high-dose formulations of both.
Research in the last decade has deepened understanding of the pathogensis of asthma and led to the development of the biologic agents that directly target the cytokines involved in causing and maintaining severe asthma symptoms.
As of 2021, GINA guidelines for the management of severe asthma include biologics as add-on therapy for severe allergic and eosinophilic asthma. Currently there are 6 biologic agents approved by the FDA for treatment of severe asthma. Get 3 essential facts on each in the following short slide show.
BEC, blood eosinophil count; FeNO, fractional concentration of exhaled nitric oxide; IgE, immunoglobulin E; IL, interleukin; mAb, monoclonal antibody; OCS, oral corticosteroid; ppb, parts per billion; Rα, receptor alpha
FDA Proposed Rule Would Limit Nicotine Content in Cigarettes, Cigars, Other Combusted Products
January 16th 2025The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.
